Get it on Google Play

Ionis receives FDA breakthrough therapy designation for ION582

September 9, 2025 7:00 AM UTC Send to a Friend
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ION582 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login